/
KALA
$0.92+$0.04 (+4.52%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$17.1M
19M shares
52-week range
$0.59 – $1,030.00
0% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-7191.88
KALA BIO, Inc. Common Stock
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
www.kalarx.com- Employees
- 6
- IPO / List date
- Jul 20, 2017
- HQ
- ARLINGTON, MA
Held by traders on TradeandTell
No one on the platform currently holds KALA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in KALA as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-05-11 | 1-for-50reverse |
| 2022-10-21 | 1-for-50reverse |
| 2022-08-26 | 1.001-for-1 |
Recent trades on TradeandTell
No one on the platform has traded KALA yet.
